MACC1, like TNM staging, predicts disease-free survival (DFS) in BC, and ROC analysis results showed that serum MACC1 measurement successfully distinguished BC patients from normal and healthy controls, with an optimal cut-off value of 38.35 pg/mL, sensitivity of 71.4%, specificity of 89.1%, and AUC of 0.766. Here, MACC1 is linked to breast cancer.